DOCSLIB.ORG

Extracellular Matrix in Development and Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

International Journal of Molecular Sciences Extracellular Matrix in Development and Disease Edited by Julia Thom Oxford Printed Edition of the Special Issue Published in International Journal of Molecular Sciences www.mdpi.com/journal/ijms Extracellular Matrix in Development and Disease Extracellular Matrix in Development and Disease Special Issue Editor Julia Thom Oxford MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade Special Issue Editor Julia Thom Oxford Boise State University USA Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal International Journal of Molecular Sciences (ISSN 1422-0067) from 2017 to 2019 (available at: https: //www.mdpi.com/journal/ijms/special issues/extracellular matrix) For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03897-570-0 (Pbk) ISBN 978-3-03897-571-7 (PDF) Cover image courtesy of Roxanne Stone and Stephanie Frahs; scanning electron micrograph acquired by Makenna Hardy, Boise State University. The cover image depicts a decellularized cartilage ECM scaffold seeded with chondrocytes. c 2019 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND. Contents About the Special Issue Editor ...................................... vii Julia Thom Oxford, Jonathon C. Reeck and Makenna J. Hardy Extracellular Matrix in Development and Disease Reprinted from: Int. J. Mol. Sci. 2019, 20, 205, doi:10.3390/ijms20010205 ............... 1 Lavinia Arseni, Anita Lombardi and Donata Orioli From Structure to Phenotype: Impact of Collagen Alterations on Human Health Reprinted from: Int. J. Mol. Sci. 2018, 19, 1407, doi:10.3390/ijms19051407 .............. 6 Salin A. Chakkalakal, Juliane Heilig, Ulrich Baumann, Mats Paulsson and Frank Zaucke Impact of Arginine to Cysteine Mutations in Collagen II on Protein Secretion and Cell Survival Reprinted from: Int. J. Mol. Sci. 2018, 19, 541, doi:10.3390/ijms19020541 ............... 42 Sara Stridh, Fredrik Palm, Tomoko Takahashi, Mayumi Ikegami-Kawai, Malou Friederich-Persson and Peter Hansell Hyaluronan Production by Renomedullary Interstitial Cells: Influence of Endothelin, Angiotensin II and Vasopressin Reprinted from: Int. J. Mol. Sci. 2017, 18, 2701, doi:10.3390/ijms18122701 .............. 59 Eva Nagyova The Biological Role of Hyaluronan-Rich Oocyte-Cumulus Extracellular Matrix in Female Reproduction Reprinted from: Int. J. Mol. Sci. 2018, 19, 283, doi:10.3390/ijms19010283 ............... 74 Yao Ye, Aurelia Vattai, Xi Zhang, Junyan Zhu, Christian J. Thaler, Sven Mahner, Udo Jeschke and Viktoria von Sch¨onfeldt Role of Plasminogen Activator Inhibitor Type 1 in Pathologies of Female Reproductive Diseases Reprinted from: Int. J. Mol. Sci. 2017, 18, 1651, doi:10.3390/ijms18081651 .............. 88 Cameron Walker, Elijah Mojares and Armando del R´ıo Hern´andez Role of Extracellular Matrix in Development and Cancer Progression Reprinted from: Int. J. Mol. Sci. 2018, 19, 3028, doi:10.3390/ijms19103028 ..............105 Shike Wang, Zhenyu Li and Ren Xu Human Cancer and Platelet Interaction, a Potential Therapeutic Target Reprinted from: Int. J. Mol. Sci. 2018, 19, 1246, doi:10.3390/ijms19041246 ..............136 Maria Del Ben, Diletta Overi, Licia Polimeni, Guido Carpino, Giancarlo Labbadia, Francesco Baratta, Daniele Pastori, Valeria Noce, Eugenio Gaudio, Francesco Angelico and Carmine Mancone Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH Reprinted from: Int. J. Mol. Sci. 2018, 19, 603, doi:10.3390/ijms19020603 ...............151 Girdhari Rijal, Jing Wang, Ilhan Yu, David R. Gang, Roland K. Chen and Weimin Li Porcine Breast Extracellular Matrix Hydrogel for Spatial Tissue Culture Reprinted from: Int. J. Mol. Sci. 2018, 19, 2912, doi:10.3390/ijms19102912 ..............165 v Kena Song, Zirui Wang, Ruchuan Liu, Guo Chen and Liyu Liu Microfabrication-Based Three-Dimensional (3-D) Extracellular Matrix Microenvironments for Cancer and Other Diseases Reprinted from: Int. J. Mol. Sci. 2018, 19, 935, doi:10.3390/ijms19040935 ...............178 Scott P. Levick and Alexander Widiapradja Mast Cells: Key Contributors to Cardiac Fibrosis Reprinted from: Int. J. Mol. Sci. 2018, 19, 231, doi:10.3390/ijms19010231 ...............192 Dimitry A. Chistiakov, Alexandra A. Melnichenko, Veronika A. Myasoedova, Andrey V. Grechko and Alexander N. Orekhov Thrombospondins: A Role in Cardiovascular Disease Reprinted from: Int. J. Mol. Sci. 2017, 18, 1540, doi:10.3390/ijms18071540 ..............210 Ilonka Rohm, Katja Grun, ¨ Linda Marleen Muller, ¨ Daniel Kretzschmar, Michael Fritzenwanger, Atilla Yilmaz, Alexander Lauten, Christian Jung, P. Christian Schulze, Alexander Berndt and Marcus Franz Increased Serum Levels of Fetal Tenascin-C Variants in Patients with Pulmonary Hypertension: Novel Biomarkers Reflecting Vascular Remodeling and Right Ventricular Dysfunction? Reprinted from: Int. J. Mol. Sci. 2017, 18, 2371, doi:10.3390/ijms18112371 ..............239 Carolyn M. Dancevic, Yann Gibert, Joachim Berger, Adam D. Smith, Clifford Liongue, Nicole Stupka, Alister C. Ward and Daniel R. McCulloch The ADAMTS5 Metzincin Regulates Zebrafish Somite Differentiation Reprinted from: Int. J. Mol. Sci. 2018, 19, 766, doi:10.3390/ijms19030766 ...............250 Natasha McRae, Leonard Forgan, Bryony McNeill, Alex Addinsall, Daniel McCulloch, Chris Van der Poel and Nicole Stupka Glucocorticoids Improve Myogenic Differentiation In Vitro by Suppressing the Synthesis of Versican, a Transitional Matrix Protein Overexpressed in Dystrophic Skeletal Muscles Reprinted from: Int. J. Mol. Sci. 2017, 18, 2629, doi:10.3390/ijms18122629 ..............262 Mario Enrique Alvar`ez Fallas, Martina Piccoli, Chiara Franzin, Alberto Sgr`o, Arben Dedja, Luca Urbani, Enrica Bertin, Caterina Trevisan, Piergiorgio Gamba, Alan J. Burns, Paolo De Coppi and Michela Pozzobon Decellularized Diaphragmatic Muscle Drives a Constructive Angiogenic Response In Vivo Reprinted from: Int. J. Mol. Sci. 2018, 19, 1319, doi:10.3390/ijms19051319 ..............284 Anna Urciuolo and Paolo De Coppi Decellularized Tissue for Muscle Regeneration Reprinted from: Int. J. Mol. Sci. 2018, 19, 2392, doi:10.3390/ijms19082392 ..............303 Bryce LaFoya, Jordan A. Munroe, Alison Miyamoto, Michael A. Detweiler, Jacob J. Crow, Tana Gazdik and Allan R. Albig Beyond the Matrix: The Many Non-ECM Ligands for Integrins Reprinted from: Int. J. Mol. Sci. 2018, 19, 449, doi:10.3390/ijms19020449 ...............314 vi About the Special Issue Editor Julia Thom Oxford, Ph.D., is a Distinguished Professor and the Stueckle Endowed Chair in the Department of Biological Sciences. She received a Doctor of Philosophy degree in Biochemistry and Biophysics in 1986 from Washington State University and completed a postdoctoral fellowship at Shriners Hospital for Children focusing on the role of extracellular matrix in skeletal development. She began working at Boise State University in 2000 and has taught courses on the Extracellular Matrix and Developmental Biology since 2001. Her current research projects focus on rare diseases, molecular mechanisms of cellular mechanoreception in bone and cartilage, the regulation of cell signaling by Col11a1 during craniofacial development, the extracellular matrix as a key factor in cancer progression, the effects of simulated microgravity on articular cartilage, the induction of early stages of osteoarthritis, biomaterials, 3-D cell culture model systems, and alternative splicing of mRNA during embryonic development. She is the Program Director of the NIH Center of Biomedical Research Excellence in Matrix Biology. vii International Journal of Molecular Sciences Editorial Extracellular Matrix in Development and Disease Julia Thom Oxford 1,2,3,4,* , Jonathon C. Reeck 1,2 and Makenna J. Hardy 1,3 1 Center of Biomedical Research Excellence in Matrix Biology, Boise State University, Boise, ID 83725-1511, USA; [email protected] (J.C.R.); [email protected] (M.J.H.) 2 Biomolecular Research Center, Boise State University, Boise, ID 83725-1511, USA 3 Biomolecular Sciences Graduate Program, Boise State University, Boise, ID 83725, USA 4 Department of Biological Science, Boise State University, Boise, ID 83725-1515, USA * Correspondence: [email protected]; Tel.: +1-208-426-2395 Received: 19 December 2018; Accepted: 4 January 2019; Published: 8 January 2019 Keywords: extracellular matrix; hereditary diseases; reproduction; cancer; muscle; tissue engineering; integrins 1. Introduction The evolution of multicellular metazoan organisms was marked by the inclusion of an extracellular matrix (ECM), a multicomponent, proteinaceous network between cells that contributes to the spatial arrangement of cells and the resulting tissue organization. The development of an ECM that provides support in larger organisms may have represented an advantage in the face of selection
Recommended publications
  • Additions and Deletions to the Drug Product List

    Additions and Deletions to the Drug Product List

    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690
  • The Skin in the Ehlers-Danlos Syndromes

    The Skin in the Ehlers-Danlos Syndromes

    EDS Global Learning Conference July 30-August 1, 2019 (Nashville) The Skin in the Ehlers-Danlos Syndromes Dr Nigel Burrows Consultant Dermatologist MD FRCP Department of Dermatology Addenbrooke’s Hospital Cambridge University NHS Foundation Trust Cambridge, UK No conflict of interests or disclosures Burrows, N: The Skin in EDS 1 EDS Global Learning Conference July 30-August 1, 2019 (Nashville) • Overview of skin and anatomy • Skin features in commoner EDS • Skin features in rarer EDS subtypes • Skin management The skin • Is useful organ to sustain life ØProtection - microorganisms, ultraviolet light, mechanical damage ØSensation ØAllows movement ØEndocrine - vitamin D production ØExcretion - sweat ØTemperature regulation Burrows, N: The Skin in EDS 2 EDS Global Learning Conference July 30-August 1, 2019 (Nashville) The skin • Is useful organ to sustain life • Provides a visual clue to diagnoses • Important for cultures and traditions • Ready material for research Skin Fun Facts • Largest organ in the body • In an average adult the skin weighs approx 5kg (11lbs) and covers 2m2 (21 sq ft) • 11 miles of blood vessels • The average person has about 300 million skin cells • More than half of the dust in your home is actually dead skin • Your skin is home to more than 1,000 species of bacteria Burrows, N: The Skin in EDS 3 EDS Global Learning Conference July 30-August 1, 2019 (Nashville) The skin has 3 main layers Within the Dermis Extracellular Matrix 1. Collagen 2. Elastic fibres 3. Ground Substances i) glycosaminoglycans, ii) proteoglycans,
  • Innate Pro–B-Cell Progenitors Protect Against Type 1 Diabetes By

    Innate Pro–B-Cell Progenitors Protect Against Type 1 Diabetes By

    Innate pro–B-cell progenitors protect against type 1 PNAS PLUS diabetes by regulating autoimmune effector T cells Ruddy Montandona,b,1, Sarantis Korniotisa,b,1, Esther Layseca-Espinosaa,b,2, Christophe Grasa,b, Jérôme Mégretc, Sophie Ezinea,d, Michel Dya,b, and Flora Zavalaa,b,3 aFaculté de Médecine Site Necker, Université Paris Descartes, bCentre National de la Recherche Scientifique Unité Mixte de Recherche 8147, 75015 Paris, France; cInstitut Fédératif de Recherche 94 Necker-Enfants Malades, 75015 Paris, France; and dInstitut National de la Santé et de la Recherche Médicale U1020, 75015 Paris, France Edited by Simon Fillatreau, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, and accepted by the Editorial Board May 6, 2013 (received for review December 24, 2012) Diverse hematopoietic progenitors, including myeloid populations emergence of regulatory B cells (Bregs), along with acquired-type arising in inflammatory and tumoral conditions and multipotent stimulation, such as B-cell receptor (BCR) engagement concomi- cells, mobilized by hematopoietic growth factors or emerging during tant or not with CD40 activation (10, 11). Such induced regulatory parasitic infections, display tolerogenic properties. Innate immune B-cell functions are believed to be more robust than those ex- stimuli confer regulatory functions to various mature B-cell subsets pressed by naive and resting B cells, which can nevertheless tolerize but immature B-cell progenitors endowed with suppressive proper- naive T cells and induce regulatory T cells (Tregs) (12, 13). ties per se or after differentiating into more mature regulatory Bregs are a heterogeneous lymphocyte subset present among all B cells remain to be characterized. Herein we provide evidence for major B-cell populations (14–17).
  • P2 Receptors in Cardiovascular Regulation and Disease

    P2 Receptors in Cardiovascular Regulation and Disease

    Purinergic Signalling (2008) 4:1–20 DOI 10.1007/s11302-007-9078-7 REVIEW P2 receptors in cardiovascular regulation and disease David Erlinge & Geoffrey Burnstock Received: 3 May 2007 /Accepted: 22 August 2007 /Published online: 21 September 2007 # Springer Science + Business Media B.V. 2007 Abstract The role of ATP as an extracellular signalling Introduction molecule is now well established and evidence is accumulating that ATP and other nucleotides (ADP, UTP and UDP) play Ever since the first proposition of cell surface receptors for important roles in cardiovascular physiology and pathophysi- nucleotides [1, 2], it has become increasingly clear that, in ology, acting via P2X (ion channel) and P2Y (G protein- addition to functioning as an intracellular energy source, the coupled) receptors. In this article we consider the dual role of purines and pyrimidines ATP, adenosine diphosphate ATP in regulation of vascular tone, released as a cotransmitter (ADP), uridine triphosphate (UTP) and uridine diphosphate from sympathetic nerves or released in the vascular lumen in (UDP) can serve as important extracellular signalling response to changes in blood flow and hypoxia. Further, molecules [3, 4] acting on 13 P2X homo- and heteromul- purinergic long-term trophic and inflammatory signalling is timer ionotropic and 8 P2Y metabotropic receptor subtypes described in cell proliferation, differentiation, migration and [5, 6] (Table 1). To terminate signalling, ectonucleotidases death in angiogenesis, vascular remodelling, restenosis and are present in the circulation and on cell surfaces, rapidly atherosclerosis. The effects on haemostasis and cardiac degrading extracellular ATP into ADP, AMP and adenosine regulation is reviewed. The involvement of ATP in vascular [7, 8].
  • 2021 Undergraduate Research Symposium Program

    2021 Undergraduate Research Symposium Program

    FORDHAM COLLEGE AT ROSE HILL 14TH ANNUAL UNDERGRADUATE RESEARCH SYMPOSIUM Wednesday, May 5, 2021 AN INTERDISCIPLINARY CELEBRATION OF OUR STUDENTS AND MENTORS The Fourteenth Annual Fordham College at Rose Hill Undergraduate Research Symposium Program | Spring 2021 Welcome to the Fourteenth Annual FCRH Research Symposium, for the first time in a hybrid format! The accomplishments of our students and mentors during the pandemic have been extraordinary and we are overjoyed to celebrate them today. From our beautiful campus, to their homes throughout the country and beyond, our undergraduate research community was always open for new discoveries. We are delighted to share 120 abstracts from over 200 students who pursued their projects during such challenging times. Their work, dedication, and determination to be a part of today’s event is inspiring and what FCRH undergraduate research is all about. We are in this together to urge each other on and findings shared today may well change the world. We are also proud to announce that the 11th volume of the Fordham Undergraduate Research Journal has been published. The FURJ team took on an enormous undertaking of running their operation in hybrid format, with a record number of submissions, and as always, they have dazzled us with the quality of their efforts. Undergraduate research has become a part of who we are at FCRH. Because of this, our program, against all odds in the past year, continues to grow, expanding across disciplines and accessible to all students in a number of ways. Students are creating new knowledge in our labs, independently with the guidance of their mentors, as part of innovative class projects, and even to support their activism.
  • Whole Exome Sequencing Gene Package Vision Disorders, Version 6.1, 31-1-2020

    Whole Exome Sequencing Gene Package Vision Disorders, Version 6.1, 31-1-2020

    Whole Exome Sequencing Gene package Vision disorders, version 6.1, 31-1-2020 Technical information DNA was enriched using Agilent SureSelect DNA + SureSelect OneSeq 300kb CNV Backbone + Human All Exon V7 capture and paired-end sequenced on the Illumina platform (outsourced). The aim is to obtain 10 Giga base pairs per exome with a mapped fraction of 0.99. The average coverage of the exome is ~50x. Duplicate and non-unique reads are excluded. Data are demultiplexed with bcl2fastq Conversion Software from Illumina. Reads are mapped to the genome using the BWA-MEM algorithm (reference: http://bio-bwa.sourceforge.net/). Variant detection is performed by the Genome Analysis Toolkit HaplotypeCaller (reference: http://www.broadinstitute.org/gatk/). The detected variants are filtered and annotated with Cartagenia software and classified with Alamut Visual. It is not excluded that pathogenic mutations are being missed using this technology. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 5 nucleotides and of somatic mosaic mutations (all types of sequence changes). HGNC approved Phenotype description including OMIM phenotype ID(s) OMIM median depth % covered % covered % covered gene symbol gene ID >10x >20x >30x ABCA4 Cone-rod dystrophy 3, 604116 601691 94 100 100 97 Fundus flavimaculatus, 248200 {Macular degeneration, age-related, 2}, 153800 Retinal dystrophy, early-onset severe, 248200 Retinitis pigmentosa 19, 601718 Stargardt disease
  • Serum Or Plasma Cartilage Oligomeric Matrix Protein Concentration As a Diagnostic Marker in Pseudoachondroplasia: Differential Diagnosis of a Family

    Serum Or Plasma Cartilage Oligomeric Matrix Protein Concentration As a Diagnostic Marker in Pseudoachondroplasia: Differential Diagnosis of a Family

    European Journal of Human Genetics (2007) 15, 1023–1028 & 2007 Nature Publishing Group All rights reserved 1018-4813/07 $30.00 www.nature.com/ejhg ARTICLE Serum or plasma cartilage oligomeric matrix protein concentration as a diagnostic marker in pseudoachondroplasia: differential diagnosis of a family A Cevik Tufan*,1,2,7, N Lale Satiroglu-Tufan2,3,7, Gail C Jackson4, C Nur Semerci3, Savas Solak5 and Baki Yagci6 1Department of Histology and Embryology, School of Medicine, Pamukkale University, Denizli, Turkey; 2Pamukkale University Research Center for Genetic Engineering and Biotechnology, Denizli, Turkey; 3Molecular Genetics Laboratory, Department of Medical Biology, Center for Genetic Diagnosis, School of Medicine, Pamukkale University, Denizli, Turkey; 4NGRL, St Mary’s Hospital, Manchester, UK; 5Birgi Medical Center, Republic of Turkey Ministry of Health, Izmir, Turkey; 6Department of Radiology, School of Medicine, Pamukkale University, Denizli, Turkey Pseudoachondroplasia (PSACH) is an autosomal-dominant osteochondrodysplasia due to mutations in the gene encoding cartilage oligomeric matrix protein (COMP). Clinical diagnosis of PSACH is based primarily on family history, physical examination, and radiographic evaluation, and is sometimes extremely difficult, particularly in adult patients. Genetic diagnosis based on DNA sequencing, on the other hand, can be expensive, time-consuming, and intensive because COMP mutations may be scattered throughout the gene. However, there is evidence that decreased plasma COMP concentration may serve as a diagnostic marker in PSACH, particularly in adult patients. Here, we report the serum and/or plasma COMP concentration-based differential diagnosis of a family with affected adult members. The mean serum and/or plasma COMP concentrations of the three affected family members alive (0.6970.15 and/or 0.8170.08 lg/ml, respectively) were significantly lower than those of an age-compatible control group of 21 adults (1.5270.37 and/or 1.3770.36 lg/ml, respectively; Po0.0001).
  • Genes in Eyecare Geneseyedoc 3 W.M

    Genes in Eyecare Geneseyedoc 3 W.M

    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
  • A Comparative Study of Molecular Structure, Pka, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs

    A Comparative Study of Molecular Structure, Pka, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs

    International Journal of Molecular Sciences Article A Comparative Study of Molecular Structure, pKa, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs Milan Remko 1,*, Anna Remková 2 and Ria Broer 3 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32 Bratislava, Slovakia 2 Department of Internal Medicine, Faculty of Medicine, Slovak Medical University, Limbová 12, SK–833 03 Bratislava, Slovakia; [email protected] 3 Department of Theoretical Chemistry, Zernike Institute for Advanced Materials, University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands; [email protected] * Correspondence: [email protected]; Tel.: +421-2-5011-7291 Academic Editor: Michael Henein Received: 18 February 2016; Accepted: 11 March 2016; Published: 19 March 2016 Abstract: Theoretical chemistry methods have been used to study the molecular properties of antiplatelet agents (ticlopidine, clopidogrel, prasugrel, elinogrel, ticagrelor and cangrelor) and several thiol-containing active metabolites. The geometries and energies of most stable conformers of these drugs have been computed at the Becke3LYP/6-311++G(d,p) level of density functional theory. Computed dissociation constants show that the active metabolites of prodrugs (ticlopidine, clopidogrel and prasugrel) and drugs elinogrel and cangrelor are completely ionized at pH 7.4. Both ticagrelor and its active metabolite are present at pH = 7.4 in neutral undissociated form. The thienopyridine prodrugs ticlopidine, clopidogrel and prasugrel are lipophilic and insoluble in water. Their lipophilicity is very high (about 2.5–3.5 logP values). The polar surface area, with regard to the structurally-heterogeneous character of these antiplatelet drugs, is from very large interval of values of 3–255 Å2.
  • Phenotype and Response to Growth Hormone Therapy in Siblings with B4GALT7 Deficiency T ⁎ Carla Sandler-Wilsona, Jennifer A

    Phenotype and Response to Growth Hormone Therapy in Siblings with B4GALT7 Deficiency T ⁎ Carla Sandler-Wilsona, Jennifer A

    Bone 124 (2019) 14–21 Contents lists available at ScienceDirect Bone journal homepage: www.elsevier.com/locate/bone Case Report Phenotype and response to growth hormone therapy in siblings with B4GALT7 deficiency T ⁎ Carla Sandler-Wilsona, Jennifer A. Wambacha, , Bess A. Marshalla,b, Daniel J. Wegnera, William McAlisterc, F. Sessions Colea,b, Marwan Shinawia a Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO 63110, USA b Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO 63110, USA c Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO 63110, USA ARTICLE INFO ABSTRACT Keywords: B4GALT7 encodes beta-1,4-galactosyltransferase which links glycosaminoglycans to proteoglycans in connective B4GALT7 tissues. Rare, biallelic variants in B4GALT7 have been associated with spondylodysplastic Ehlers-Danlos and Spondylodysplastic Ehlers-Danlos syndrome Larsen of Reunion Island syndromes. Thirty patients with B4GALT7-related disorders have been reported to date Larsen of Reunion Island syndrome with phenotypic variability. Using whole exome sequencing, we identified male and female siblings with bial- Growth hormone lelic, pathogenic B4GALT7 variants and phenotypic features of spondylodysplastic Ehlers-Danlos syndrome as Proteoglycan well as previously unreported skeletal characteristics. We also provide detailed radiological
  • Ophthalmology

    Ophthalmology

    Ophthalmology Information for health professionals MEDICAL GENETIC TESTING FOR OPHTHALMOLOGY Recent technologies, in particularly Next Generation Sequencing (NGS), allows fast, accurate and valuable diagnostic tests. For Ophthalmology, CGC Genetics has an extensive list of medical genetic tests with clinical integration of results by our Medical Geneticists. 1. EXOME SEQUENCING: Exome Sequencing is a very efficient strategy to study most exons of a patient’s genome, unraveling mutations associated with specific disorders or phenotypes. With this diagnostic strategy, patients can be studied with a significantly reduced turnaround time and cost. CGC Genetics has available 2 options for Exome Sequencing: • Whole Exome Sequencing (WES), which analyzes the entire exome (about 20 000 genes); • Disease Exome by CGC Genetics, which analyzes about 6 000 clinically-relevant genes. Any of these can be performed in the index case or in a Trio. 2. NGS PANELS For NGS panels, several genes associated with the same phenotype are simultaneously sequenced. These panels provide increased diagnostic capability with a significantly reduced turnaround time and cost. CGC Genetics has several NGS panels for Ophthalmology that are constantly updated (www.cgcgenetics.com). Any gene studied in exome or NGS panel can also be individually sequenced and analyzed for deletion/duplication events. 3. EXPERTISE IN MEDICAL GENETICS CGC Genetics has Medical Geneticists specialized in genetic counseling for ophthalmological diseases who may advice in choosing the most appropriate
  • Pathophysiological Significance of Dermatan Sulfate Proteoglycans Revealed by Human Genetic Disorders

    Pathophysiological Significance of Dermatan Sulfate Proteoglycans Revealed by Human Genetic Disorders

    Title Pathophysiological Significance of Dermatan Sulfate Proteoglycans Revealed by Human Genetic Disorders Author(s) Mizumoto, Shuji; Kosho, Tomoki; Yamada, Shuhei; Sugahara, Kazuyuki Pharmaceuticals, 10(2), 34 Citation https://doi.org/10.3390/ph10020034 Issue Date 2017-06 Doc URL http://hdl.handle.net/2115/67053 Rights(URL) http://creativecommons.org/licenses/by/4.0/ Type article File Information pharmaceuticals10-2 34.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP pharmaceuticals Review Pathophysiological Significance of Dermatan Sulfate Proteoglycans Revealed by Human Genetic Disorders Shuji Mizumoto 1,*, Tomoki Kosho 2, Shuhei Yamada 1 and Kazuyuki Sugahara 1,* 1 Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya 468-8503, Japan; [email protected] 2 Center for Medical Genetics, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan; [email protected] * Correspondence: [email protected] (S.M.); [email protected] (K.S.); Tel.: +81-52-839-2652 Academic Editor: Barbara Mulloy Received: 22 February 2017; Accepted: 24 March 2017; Published: 27 March 2017 Abstract: The indispensable roles of dermatan sulfate-proteoglycans (DS-PGs) have been demonstrated in various biological events including construction of the extracellular matrix and cell signaling through interactions with collagen and transforming growth factor-β, respectively. Defects in the core proteins of DS-PGs such as decorin and